A new three-year project is underway at The University of Aberdeen’s Rowett Institute and University College London to research mechanisms to bypass the side effects that come with using obesity drugs.
Glucagon-like peptide-1 receptor (GLP1)-based medicines such as Ozempic (semaglutide) act in the brain to reduce food intake and have quickly become one of the most effective pharmaceutical tools to tackle obesity.
Free access provides up to 10 articles
Subscription options start at $5 per month
which is less than a Starbucks coffee!